Neumora Therapeutics Common StockNASDAQ: NMRA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 September 2023

Next earnings report:

07 March 2025

Last dividends:

N/A

Next dividends:

N/A
$1.58 B
-49%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector
-43%vs. 3y high
82%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 9 min ago
$9.81+$0.02(+0.20%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

NMRA Latest News

This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho
marketwatch.com13 November 2024 Sentiment: POSITIVE

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
globenewswire.com12 November 2024 Sentiment: POSITIVE

Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025

Neumora Therapeutics to Participate in Upcoming Conferences in November
globenewswire.com06 November 2024 Sentiment: POSITIVE

WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in November:

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation
globenewswire.com20 June 2024 Sentiment: POSITIVE

NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
Zacks Investment Research16 April 2024 Sentiment: NEGATIVE

The FDA has halted Neumora's phase I study of NMRA-266 for certain neuropsychiatric disorders, causing a drop in the company's stock price.

Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?
InvestorPlace15 April 2024 Sentiment: NEGATIVE

The stock of Neumora Therapeutics is dropping on Monday following the company's announcement of a clinical hold on a Phase 1 trial for NMRA-266, with the FDA responsible for this decision.

Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick
Zacks Investment Research10 January 2024 Sentiment: POSITIVE

Neumora Therapeutics (NMRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Neumora Therapeutics to Participate in Upcoming Conferences in November
GlobeNewsWire30 October 2023 Sentiment: POSITIVE

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November:

Why Shares of Neumora Therapeutics Slumped This Week
The Motley Fool21 September 2023 Sentiment: NEGATIVE

Neumora focuses on central nervous system disorders. Its lead therapy is Navacaprant to treat MDD.

What type of business is Neumora Therapeutics Common Stock?

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

What sector is Neumora Therapeutics Common Stock in?

Neumora Therapeutics Common Stock is in the Healthcare sector

What industry is Neumora Therapeutics Common Stock in?

Neumora Therapeutics Common Stock is in the Biotechnology industry

What country is Neumora Therapeutics Common Stock from?

Neumora Therapeutics Common Stock is headquartered in United States

When did Neumora Therapeutics Common Stock go public?

Neumora Therapeutics Common Stock initial public offering (IPO) was on 15 September 2023

What is Neumora Therapeutics Common Stock website?

https://www.neumoratx.com

Is Neumora Therapeutics Common Stock in the S&P 500?

No, Neumora Therapeutics Common Stock is not included in the S&P 500 index

Is Neumora Therapeutics Common Stock in the NASDAQ 100?

No, Neumora Therapeutics Common Stock is not included in the NASDAQ 100 index

Is Neumora Therapeutics Common Stock in the Dow Jones?

No, Neumora Therapeutics Common Stock is not included in the Dow Jones index

When was Neumora Therapeutics Common Stock the previous earnings report?

No data

When does Neumora Therapeutics Common Stock earnings report?

The next expected earnings date for Neumora Therapeutics Common Stock is 07 March 2025